Piramal PharmaNSE:PPLPHARMA -2.75%53 EBITDA Margin % is 12.51% as of Mar. 2026, which is 26% below its 10-year median of 16.86. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 53/100 and a GF Value™ of ₹175.28 (Fairly Valued). The stock has 3 warning signs investors should review. Among 952 Drug Manufacturers companies, Piramal Pharma ranks worse than 53.05% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Piramal Pharma's EBITDA for the
three
months ended in Mar. 2026 was ₹3,444 Mil. Piramal Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹27,518 Mil. Therefore, Piramal Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 12.51%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Piramal Pharma EBITDA Margin % Related Terms
Piramal Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Piramal Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Piramal Pharma (NSE:PPLPHARMA) has a EBITDA Margin % of 12.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Piramal Pharma and its competitors. This is 26% below median its historical median of 16.86. Over the past decade, Piramal Pharma's EBITDA Margin % has ranged from 11.23 to 19.47. According to the industry distribution chart, Piramal Pharma ranks #505 out of 952 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is Piramal Pharma's EBITDA Margin % too high?
Piramal Pharma's current EBITDA Margin % of 12.51% is 26% below median its 10-year median of 16.86. Over the past 10 years, this metric has ranged from a low of 11.23 to a high of 19.47. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Piramal Pharma's value of 12.51% is 0.3% above this industry median. Based on the distribution chart, Piramal Pharma ranks #505 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Piramal Pharma has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #505 out of 952 companies for EBITDA Margin %. This places Piramal Pharma in the lower half of its industry. The industry median EBITDA Margin % is 12.47. Piramal Pharma's value of 12.51% is 0.3% above this benchmark. Historically, Piramal Pharma's own EBITDA Margin % has ranged from 11.23 to 19.47 over the past decade. While the company's 10-year median is 16.86 vs. the industry median of 12.47, Piramal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current EBITDA Margin % of 12.51% is 0.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current EBITDA Margin % is 12.51%, which is 26% below median its own 10-year median of 16.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹175.28, compared to a current price of ₹167.69 — trading 4.3% below its estimated fair value. The current EBITDA Margin % is 12.51%, which is 26% below median its 10-year median of 16.86 and 0.3% above the Drug Manufacturers industry median of 12.47. Piramal Pharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current EBITDA Margin % is 12.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be undervalued.
The current stock price of ₹167.69 is trading 4.3% below its estimated GF Value™ of ₹175.28.
GuruFocus considers Piramal Pharma to be Fairly Valued.
Key valuation signals for NSE:PPLPHARMA:
EBITDA Margin %: 12.51% (26% below median its 10-year median of 16.86)
GF Value™: ₹175.28 vs. price of ₹167.69 (4.3% below fair value)
Industry Position: 0.3% above the Drug Manufacturers median (#505 of 952)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
53GF Score
Get the complete analysis for NSE:PPLPHARMA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
